BUSINESS SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table is a summary of segment information for the years ended December 31, 2020, 2019 and 2018. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2.

	2020		2019		2018
Net revenues:
DIS business	$	9,139	$	7,405	$	7,204
All other operating segments	298		321		327
Total net revenues	$	9,437	$	7,726	$	7,531
Operating earnings (loss):
DIS business	$	2,201	$	1,298	$	1,235
All other operating segments	39		42		47
General corporate activities	(269)		(109)		(181)
Total operating income	1,971		1,231		1,101
Non-operating expenses, net	(87)		(155)		(175)
Income from continuing operations before income taxes and equity in earnings of equity method investees	1,884		1,076		926
Income tax expense	(460)		(247)		(182)
Equity in earnings of equity method investees, net of taxes	75		57		44
Income from continuing operations	1,499		886		788
Income from discontinued operations, net of taxes	—		20		—
Net income	1,499		906		788
Less: Net income attributable to noncontrolling interests	68		48		52
Net income attributable to Quest Diagnostics	$	1,431	$	858	$	736

    Depreciation and amortization expense for the years ended December 31, 2020, 2019 and 2018 were as follows:

	2020		2019		2018
DIS business	$	249	$	226	$	213
All other operating segments	8		6		6
General corporate	104		97		90
Total depreciation and amortization	$	361	$	329	$	309

    Capital expenditures for the years ended December 31, 2020, 2019 and 2018 were as follows:

	2020		2019		2018
DIS business	$	394	$	373	$	330
All other operating segments	15		20		16
General corporate	9		7		37
Total capital expenditures	$	418	$	400	$	383

    Net revenues by major service for the years ended December 31, 2020, 2019 and 2018 were as follows:

	2020		2019		2018
Routine clinical testing services	$	3,836	$	4,206	$	4,217
COVID-19 testing services	2,723		—		—
Gene-based and esoteric (including advanced diagnostics) testing services	2,098		2,620		2,409
Anatomic pathology testing services	482		579		578
All other	298		321		327
Total net revenues	$	9,437	$	7,726	$	7,531